Eric Murphy (Kinnate)

Or­biMed takes point on a new biotech launch, but al­most every­thing re­mains se­cret for now

If you missed the news of a new com­pa­ny launch backed by blue-chip in­vestor Or­biMed ear­ly Wednes­day morn­ing, that was by de­sign.

Al­terome Ther­a­peu­tics qui­et­ly emerged from stealth with $64 mil­lion in its Se­ries A, a fair­ly large sum for an ini­tial biotech raise. One would think, giv­en the in­dus­try’s pen­chant for bom­bast, such a raise would be ac­com­pa­nied by all the fan­fare that comes with an Or­biMed back­ing and enough cash to buy hun­dreds up­on hun­dreds of the most ex­pen­sive Tes­la mod­el.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.